quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:00:00·128d
PRRelease
Inhibrx Biosciences Inc. logo

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

INBX· Inhibrx Biosciences Inc.
Health Care
Original source

Companies

  • INBX
    Inhibrx Biosciences Inc.
    Health Care

Recent analyst ratings

  • Apr 8UpdateStifel$150.00
  • Jul 23UpdateJMP Securities-
  • Jan 23UpdateJMP Securities-
  • Mar 16UpdateSMBC Nikko$40.00
  • Mar 2UpdateJMP Securities$40.00
  • Nov 10UpdateCredit Suisse$53.00

Related

  • SEC14h
    SEC Form DEFA14A filed by Inhibrx Biosciences Inc.
  • SEC14h
    SEC Form DEF 14A filed by Inhibrx Biosciences Inc.
  • PR2d
    Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
  • SEC2d
    Inhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • ANALYST15d
    Stifel initiated coverage on Inhibrx Biosciences with a new price target
  • SEC35d
    Inhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC35d
    SEC Form 10-K filed by Inhibrx Biosciences Inc.
  • PR35d
    Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022